A pilot study to evaluate the development of resistance to nevirapine in asymptomatic human immunodeficiency virus-infected patients with cd4 cell counts of >500/mm3: Aids clinical trials group protocol 208

Journal of Infectious Diseases

Volumn 172, Issue 5, 1995, Pages 1379-1383

  Havlir, Diane ^a,b,c   Mc Laughlin, Margaret M ^a,b,c,d   Richman, Douglas D ^a,b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^d PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; NEVIRAPINE; VIRUS RNA;

ARTICLE; BODY BURDEN; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG RESISTANCE; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MALE; MONONUCLEAR CELL; ORAL DRUG ADMINISTRATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SYMPTOMATOLOGY; T LYMPHOCYTE SUBPOPULATION;

ANTIVIRAL AGENTS; CD4 LYMPHOCYTE COUNT; CLINICAL TRIALS; DRUG RESISTANCE, MICROBIAL; FEMALE; HIV; HIV SEROPOSITIVITY; HUMAN; IMMUNOSUPPRESSION; MALE; NEVIRAPINE; PILOT PROJECTS; POLYMERASE CHAIN REACTION; PYRIDINES; REGRESSION ANALYSIS; RNA, VIRAL; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; TIME FACTORS;

EID: 0028859469     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/172.5.1379     Document Type: Article

References (14)

1. Richman DD, Shih CK, Lowy I, et al. Human immunodeficiency virus type 1 mutants resistant to nonnucleoside inhibitors of reverse transcriptase arise in tissue culture. Proc Natl Acad Sci USA 1991;88:11241-11245
2. Cheeseman SH, Havlir D, McLaughlin M, et al. Phase I/II evaluation of nevirapine alone and in combination with zidovudine for infection with human immunodeficiency virus. J Acquir Immune Defic Syndr Hum Retrovirol 1995;8:141-151
3. Saag MS, Emini EA, Laskin OL, et al. A short-term clinical evaluation of L-697, 661, a non-nucleoside inhibitor of HIV-1 reverse transcriptase. N Eng! J Med 1993;329:1065-1072
4. Havlir D, Cheeseman SH, McLaughlin M, et al. High dose nevirapine: safety pharmacokinetics and antiviral effects in patients with human immunodeficiency virus infection. J Infect Dis 1995;171:537-545
5. Freimuth B, Davey R, Batts D, et al. Phase II clinical trials of delavirdine mesylate combination therapy [abstract 512B, vol 2]. In: Program and abstracts: X International Conference on AIDS/V STD World Congress (Yokohama, Japan), August 1994:59
6. Richman DD, Havlir D, Corbeil J, et al. Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy. J Virol 1994;68:1660-1666
7. de Jong MD, Loewenthal M, Boucher CA, et al. Alternating nevirapine and zidovudine treatment of human immunodeficiency virus type 1 -infected persons does not prolong nevirapine activity. J Infect Dis 1994;169:1346-1350
8. Embretson J, Zupancic M, Ribas JL, et al. Massive covert infection of helper T lymphocytes and macrophages by HIV during the incubation period of AIDS. Nature 1993;362:359-362
9. Pantaleo G, Graziosi C, Demarest JF, et al. HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature 1993;362:355-358
10. Wei X, Ghosh SK, Taylor ME, et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995;373:117-122
11. Ho DD, Neumann AU, Perelson AL, Chen W, Leonard JM, Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995;373:123-126
12. Coffin JM. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science 1995;267:483-489
13. Piatek M Jr, Saag MS, Yang LC, et al. High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR. Science 1993;259:1749-1754
14. Winters MA, Tan LB, Katzenstein DA, Merigan TC. Biological variation and quality control of plasma human immunodeficiency virus type 1 RNA quantitation by reverse transcriptase polymerase chain reaction. J Clin Microbiol 1993;31:2960-2966